Health-care shares were generally higher in pre-market trade
In health-care stocks news, Astrazeneca (
) gets cleared in a Department of Justice investigation into PLATO,
a major clinical trial used to win marketing approval for the
company's important new heart drug Brilinta.
AZN said the DOJ closed the probe into the 18,000-patient study
and no further action was planned.
Separately, the company reported positive results with an
experimental antibiotic called ceftazidime-avibactam as a treatment
for hospitalized adult patients with complicated intra-abdominal
And, Actavis (
) confirmed positive topline results from RECLAIM-1 and -2, pivotal
Phase III studies evaluating the potential for the investigational
antibiotic, ceftazidime-avibactam as a treatment for adult
hospitalized patients with complicated intra-abdominal
ACT trades in a 52-week range of $130.06 to $230.77, with shares
having closed up 1.2% in Monday's session.
Finally, Medtronic (
) reported Q1 adjusted EPS of $0.93, a penny ahead of the analyst
consensus on Capital IQ.
Revenue was $4.27 billion, just topping the Street consensus of
For the FY, the company reaffirmed it expects adjusted EPS of
$4.00 to $4.10 and revenue growth of 3% to 5%. The Street stands at
$4.03 per share in earnings on $18.1 billion in revenue.
Copyright (C) 2014 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.